Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across …
B Ricciuti, X Wang, JV Alessi, H Rizvi… - JAMA …, 2022 - jamanetwork.com
Importance Although tumor mutation burden (TMB) has been explored as a potential
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about
the optimal TMB threshold that best discriminates improved outcomes of immune checkpoint
inhibitor therapy among patients with non–small cell lung cancer (NSCLC). Objectives To
determine the association between increasing TMB levels and immunotherapy efficacy
across clinically relevant programmed death ligand–1 (PD-L1) levels in patients with …
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about
the optimal TMB threshold that best discriminates improved outcomes of immune checkpoint
inhibitor therapy among patients with non–small cell lung cancer (NSCLC). Objectives To
determine the association between increasing TMB levels and immunotherapy efficacy
across clinically relevant programmed death ligand–1 (PD-L1) levels in patients with …
